> top > docs > PubMed:24490627 > annotations

PubMed:24490627 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-103 Sentence denotes Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
T2 104-117 Sentence denotes INTRODUCTION:
T3 118-224 Sentence denotes Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems.
T4 225-404 Sentence denotes Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation.
T5 405-644 Sentence denotes Belimumab, a human anti-B-cell activating factor (BLyS) monoclonal antibody, was invented by Human Genome Sciences and co-developed with GlaxoSmithKline and became, in 2011, the first new therapy approved for SLE patients in over 50 years.
T6 645-659 Sentence denotes AREAS COVERED:
T7 660-852 Sentence denotes Belimumab approval represents a milestone as a new treatment for a subset of SLE patients and also a window onto the continued unmet need for many patients suffering from this diverse disease.
T8 853-1059 Sentence denotes This paper analyses the drugs and clinical trials of industry-sponsored development programs to profile the current SLE landscape and to consider how belimumab is shaping the future of SLE drug development.
T9 1060-1075 Sentence denotes EXPERT OPINION:
T10 1076-1273 Sentence denotes Our analysis demonstrates that the belimumab clinical program created a model for improvements in study designs that is reflected in ongoing clinical trials sponsored by a broad range of companies.
T11 1274-1380 Sentence denotes Additional BLyS inhibitors, with distinctive targeting characteristics, are now in late stage development.
T12 1381-1563 Sentence denotes A broad range of drugs with other mechanisms of action are also under investigation in Phase II - III trials, some of which are focused on the underserved lupus nephritis population.
T1 0-103 Sentence denotes Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
T2 104-117 Sentence denotes INTRODUCTION:
T3 118-224 Sentence denotes Systemic lupus erythematosus (SLE) is a diverse autoimmune disease affecting many different organ systems.
T4 225-404 Sentence denotes Although disease manifestations are varied across the lupus population, the widespread presence of autoantibodies indicates that SLE immunopathology involves B-cell dysregulation.
T5 405-644 Sentence denotes Belimumab, a human anti-B-cell activating factor (BLyS) monoclonal antibody, was invented by Human Genome Sciences and co-developed with GlaxoSmithKline and became, in 2011, the first new therapy approved for SLE patients in over 50 years.
T6 645-659 Sentence denotes AREAS COVERED:
T7 660-852 Sentence denotes Belimumab approval represents a milestone as a new treatment for a subset of SLE patients and also a window onto the continued unmet need for many patients suffering from this diverse disease.
T8 853-1059 Sentence denotes This paper analyses the drugs and clinical trials of industry-sponsored development programs to profile the current SLE landscape and to consider how belimumab is shaping the future of SLE drug development.
T9 1060-1075 Sentence denotes EXPERT OPINION:
T10 1076-1273 Sentence denotes Our analysis demonstrates that the belimumab clinical program created a model for improvements in study designs that is reflected in ongoing clinical trials sponsored by a broad range of companies.
T11 1274-1380 Sentence denotes Additional BLyS inhibitors, with distinctive targeting characteristics, are now in late stage development.
T12 1381-1563 Sentence denotes A broad range of drugs with other mechanisms of action are also under investigation in Phase II - III trials, some of which are focused on the underserved lupus nephritis population.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 118-146 HP_0002725 denotes Systemic lupus erythematosus
T2 166-184 HP_0002960 denotes autoimmune disease
T3 166-176 HP_0002960 denotes autoimmune

Allie

Id Subject Object Predicate Lexical cue
SS1_24490627_2_0 118-146 expanded denotes Systemic lupus erythematosus
SS2_24490627_2_0 148-151 abbr denotes SLE
AE1_24490627_2_0 SS1_24490627_2_0 SS2_24490627_2_0 abbreviatedTo Systemic lupus erythematosus,SLE